Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVERSE-Long COVID: Baricitinib for Long COVID Related Cognitive Impairment and ADRD
NCT05858515Phase 3Withdrawn
- Sponsor
- Vanderbilt University Medical Center
- Start
- Oct 2024
- Primary completion
- Dec 2027
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of baricitinib in post acute COVID-19 syndrome (2 arms), sponsored by Vanderbilt University Medical Center. Primary endpoints: Enrollment at 6 months, Diversity in enrollment at 6 months and 5 more. Planned start Oct 2024; status: withdrawn.
02
Drugs
baricitinib
03
Conditions
post acute COVID-19 syndrome
Beyond the preview
Go deeper on NCT05858515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05858515.